Introduction

The present invention refers to a method for the diagnosis and/or monitoring of the active or previous infection from Aspergillus fumigatus which comprises carrying out an in vitro immunoenzymatic assay (ELISPOT) wherein the sample, from biological fluids drawn from the patient, is placed in contact with an antigen of Aspergillus fumigatus.

Technical features

The patent relates to the use of ELISPOT assay for the identification/counting of Aspergillus-specific IFN-g and IL-10 producing T cells, to determine a ratio between the IFN-g producers and the IL-10 producers, in order to define the infection risk, for the diagnosis of Invasive Aspergillosis (IA), for the monitoring of the infection and for improving the clinical management of patients at risk and/or affected by IA.

Possible Applications

• Biotechnology Company;
• Pharmaceutical Company.

Advantages

• Early diagnosis of Invasive Aspergillosis (IA);
• Monitoring of active or previous infection;
• Correct administration of antifungal therapy.